
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
RNLXY | OTC Markets | USD | Delayed | |
RENX | London | GBP | Real-time |
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management kidney diseases in the United States. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. It has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; and partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model to improve kidney health and reduce kidney disease progression and kidney failure. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. The company was incorporated in 2018 and is based in New York, New York.
Name | Age | Since | Title |
---|---|---|---|
Fergus Fleming | 57 | 2018 | CTO & Executive Director |
Julian Huw Baines | 60 | 2024 | Executive Chairman |
Christopher Harwood-Bernard Mills | 72 | 2018 | Independent Non-Executive Director |
Catherine Coste | 58 | 2023 | Independent Non-Executive Director |
James R. McCullough | 56 | 2018 | CEO & Director |
Barry I. Freedman | - | - | Member of Clinical Advisory Board |
Joseph A. Vassalotti | - | 2019 | Member of Clinical Advisory Board |
Ralph A. Defronzo | - | 2023 | Member of Clinical Advisory Board |
Stephen Brunton | - | 2023 | Member of Clinical Advisory Board |
Erik Kristian Lium | 57 | 2018 | Independent Non-Executive Director |
Javier Morales | - | 2023 | Member of Clinical Advisory Board |
Holly J. Mattix-Kramer | - | 2023 | Member of Clinical Advisory Board |
Robert Graham Naylor | 51 | 2024 | Non-Executive Director |
Eugene E. Wright | - | 2023 | Member of Clinical Advisory Board |
Matthew Jay Budoff | - | 2023 | Member of Clinical Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review